REG - OptiBiotix Health - Result of AGM
RNS Number : 5612SOptiBiotix Health PLC09 July 2020OptiBiotix Health plc
("OptiBiotix" or the "Company")
Result of AGM
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
Due to being unable to attend the AGM in person as a result of the ongoing pandemic, shareholders were given the option to submit questions in advance. These questions have been addressed and will be available to view on the website, along with the voting results, later today: https://www.optibiotix-ir.com/content/investors/shareholder-information
For further information, please contact:
OptiBiotix Health plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD)
Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker)
Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd
Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than 20 international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDRAGRLMMTMTTMBAM
Recent news on OptiBiotix Health
See all newsREG - OptiBiotix Health - Holding(s) in Company
AnnouncementREG - AIM - AIM Notice - 28/03/2024
AnnouncementREG - OptiBiotix Health - Placing, Subscription and Director Dealing
AnnouncementREG - SkinBioTherapeutics OptiBiotix Health - Holding(s) in Company
AnnouncementREG - OptiBiotix Health - Partnership agreement with Morepen for SlimBiome
Announcement